SEC Form 4 · accession 0001628280-26-056898
Arcutis Biotherapeutics, Inc. · ARQT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick Burnett
Officer — See Remarks
Period of report
Aug 11, 2026
Accepted (ET)
Aug 13, 2026 · 8:06 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001787306
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 11, 2026 | M | 8,300 | $3.64 | A | 127,589 | D | |
| Common StockF2 | Aug 11, 2026 | S | 8,300 | $26.5216 | D | 119,289 | D | |
| Common Stock | Aug 12, 2026 | M | 6,700 | $3.64 | A | 125,989 | D | |
| Common StockF3 | Aug 12, 2026 | S | 6,700 | $26.0847 | D | 119,289 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $3.64 | Aug 11, 2026 | M | 8,300 | D | — | Jan 12, 2034 | Common Stock | 8,300 | 135,450 | D |
| Stock Option (right to buy)F1 | $3.64 | Aug 12, 2026 | M | 6,700 | D | — | Jan 12, 2034 | Common Stock | 6,700 | 128,750 | D |
Explanation of responses
- F1On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.
- F2The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.50 to $26.57, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.19, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Remarks
Reporting Person's title: EVP, Chief Medical Officer